Search

Your search keyword '"Carcassi, C."' showing total 390 results
Start Over Author "Carcassi, C."
390 results on '"Carcassi, C."'

1. Organ donation from patients with a rare disease is often safe: the italian guidelines

Author

Dallapiccola, B, Moriconi, S, Rugge, M, Cardillo, M, Carcassi, C, Colledan, M, Strologo, L, Vici, C, Facchin, P, Gridelli, B, La Rocca, V, Lombardini, L, Mazzucato, M, Peritore, D, Amoroso, A, Dallapiccola B., Moriconi S., Rugge M., Cardillo M., Carcassi C., Colledan M., Strologo L. D., Vici C. D., Facchin P., Gridelli B., La Rocca V., Lombardini L., Mazzucato M., Peritore D., Amoroso A., Dallapiccola, B, Moriconi, S, Rugge, M, Cardillo, M, Carcassi, C, Colledan, M, Strologo, L, Vici, C, Facchin, P, Gridelli, B, La Rocca, V, Lombardini, L, Mazzucato, M, Peritore, D, Amoroso, A, Dallapiccola B., Moriconi S., Rugge M., Cardillo M., Carcassi C., Colledan M., Strologo L. D., Vici C. D., Facchin P., Gridelli B., La Rocca V., Lombardini L., Mazzucato M., Peritore D., and Amoroso A.

Abstract

Although a disease is defined as rare when it has a prevalence of less than 1:2000, the overall prevalence of rare diseases in the population is greater than 1%. Among potential organ donors, a similar frequency is observed. To date, guidelines have not been established, and operational decisions have been made empirically, case- by-case, based on the experience and expertise of clinicians. For this reason, the Italian Superior Health Council (CSS) has appointed a working Group to address “patients with a rare disease as potential organ donors,” with the aim of devising recommendations for the management of transplant cases in which the donors have a rare disease. This group evaluated 493 diseases (10% of all rare diseases, including over 95% of patients with a rare disease) to deliver a technical report dealing with the suitability of organ donation and transplantation, with a focus on the organs most frequently used, including kidney, liver, heart, lung, and pancreas. This work has made it clear that a rare disease “per se” does not contraindicate organ donation at all. Indeed, in donors affected by a rare disease, almost 80% of the organs are suitable for transplantation, approximately 7% are unsuitable, and approximately 14% are suitable as non-standard with an acceptable risk.

Published
2022

4. Use of DPB1 T-cell epitope algorithm among italian transplant centers: A survey on behalf of Associazione Italiana di Immunogenetica e Biologia dei Trapianti

Author

Crocchiolo, R., Mele, L., Testi, M., Scollo Chiara, M., Murgia, B., Rossi, A., Vecchiato, C., Grammatico, P., Mininni, D., Longhi, E., Manfroi, S., Giuliodori, S., Castellani, L., Carella, G., Lai, S., Azzaro Maria, P., Mazzi, B., Perotti, L., Penta, R., Lombardo, C., Tognellini, R., Andreani, M., Albergoni Maria, P., Nesci, S., Cappuzzo, V., Chiusolo, Patrizia, Garino, E., Cappucci, G., Ceschini, N., Bevilacqua, E., Guizzardi, E., Tagliaferri Cinzia, M., Piazza, A., Carcassi, C., Miotti, V., Chiusolo P. (ORCID:0000-0002-1355-1587), Crocchiolo, R., Mele, L., Testi, M., Scollo Chiara, M., Murgia, B., Rossi, A., Vecchiato, C., Grammatico, P., Mininni, D., Longhi, E., Manfroi, S., Giuliodori, S., Castellani, L., Carella, G., Lai, S., Azzaro Maria, P., Mazzi, B., Perotti, L., Penta, R., Lombardo, C., Tognellini, R., Andreani, M., Albergoni Maria, P., Nesci, S., Cappuzzo, V., Chiusolo, Patrizia, Garino, E., Cappucci, G., Ceschini, N., Bevilacqua, E., Guizzardi, E., Tagliaferri Cinzia, M., Piazza, A., Carcassi, C., Miotti, V., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

The HLA-DPB1 locus has been demonstrated to have a significant role on patients' outcome after allogeneic HSCT, and the so-called T-cell epitope (TCE) algorithm has been incorporated in international guidelines for the selection of unrelated donors. The purpose of the present study is to measure, through a national survey conducted on behalf of the Associazione Italiana di Immunogenetica e Biologia dei Trapianti (AIBT), the extent of awareness and use of HLA-DPB1 TCE-based algorithms during the donor search. 89% of the HLA laboratories answered to a short questionnaire and the results showed a progressive increase of the laboratories typing DPB1 in patients and their potential donors during the search (from 44% to 79% during the 2010–2019 period) as well as the application of a TCE-based algorithm for the donor choice whenever possible (from 24% to 65% during the same period). The DP-permissiveness status is detailed in the official HLA typing report by 12%, 32% and 50% of laboratories in 2010, 2015 and 2019, respectively. The present data indicate an encouraging raise in the awareness of the HLA-DPB1 role in unrelated donor selection; noteworthy, mentioning the TCE-based permissiveness status in the HLA typing report of each potential unrelated donor represents a notable mean to raise awareness among transplant physicians and to support them in their task of choosing the best donor. Nonetheless, despite the compelling evidence of the predictive ability of TCE-based algorithms, further efforts are still needed to extend its application to all transplant centers in Italy.

Published
2021

7. The distribution of KIR-HLA functional blocks is different from North to South of Italy

Author

Fasano, M. E., Rendine, S., Pasi, A., Bontadini, A., Cosentini, E., Carcassi, C., Capittini, C., Cornacchini, G., de Arias, Espadas A., Garbarino, L., Carella, G., Mariotti, M. L., Mele, L., Miotti, V., Moscetti, A., Nesci, S., Ozzella, G., Piancatelli, D., Porfirio, B., Riva, M. R., Romeo, G., Tagliaferri, C., Lombardo, C., Testi, M., Amoroso, A., and Martinetti, M.

Published
2014
Full Text
View/download PDF

19. P.305 Convergent sequencing and microarray data analyses suggest the involvement of miRNAs and target mRNAs in lithium response in bipolar disorder

Author

Squassina, A., primary, Pisanu, C., additional, Papadima, E. Merkouri, additional, Melis, C., additional, Calza, S., additional, Congiu, D., additional, Loizedda, A., additional, Orrù, N., additional, Severino, G., additional, Ardau, R., additional, Chillotti, C., additional, Orrù, S., additional, Carcassi, C., additional, and Del Zompo, M., additional

Published
2019
Full Text
View/download PDF

20. A genetic epidemiology study of congenital adrenal hyperplasia in Italy

Author

Gialluisi, A, Menabò, S, Baldazzi, L, Casula, L, Meloni, A, Farci, M. C, Mariotti, S, Balestrino, L, ORTOLANO, RITA, Murru, S, Carcassi, C, Loche, S, Balsamo, A, ROMEO, GIOVANNI, Gialluisi, A, Menabò, S, Baldazzi, L, Casula, L, Meloni, A, Farci, M. C, Mariotti, S, Balestrino, L, Ortolano, R, Murru, S, Carcassi, C, Loche, S, Balsamo, A, and Romeo, G.

Subjects
Male, endocrine system diseases, Adolescent, Genotype, CYP21A2 mutations, 21-hydroxylase deficiency, Sardinia, autosomal recessive disorders, congenital adrenal hyperplasia, newborn screening, pathogenic allele frequency, prevalence, urologic and male genital diseases, Neonatal Screening, Gene Frequency, Humans, Point Mutation, Child, Molecular Epidemiology, autosomal recessive disorder, Adrenal Hyperplasia, Congenital, Infant, Newborn, Infant, CYP21A2 mutation, Italy, Child, Preschool, Female, Steroid 21-Hydroxylase
Abstract

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD-CAH) is an autosomal recessive disorder affecting steroidogenesis, due to mutations in CYP21A2 (6p21.3). 21OHD-CAH neonatal screening is based on 17-hydroxyprogesterone (17OHP) serum levels, showing high type I error rate and low sensitivity to mild CAH forms. Here, we used an epidemiological approach, which estimates the allelic frequency (q) of an autosomal recessive disorder using the proportion of homozygous patients, the mutational spectrum and the inbreeding coefficient in a sample of affected individuals. We applied this approach to 2 independent Italian cohorts of patients with both clinical and molecular diagnosis of 21OHD-CAH from mainland Italy (N = 240) and Sardinia (N = 53). We inferred q estimates of 2.87% and 1.83%, corresponding to a prevalence of 1/1214 and 1/2986, respectively. CYP21A2 mutational spectra were quite discrepant between the 2 cohorts, with V281L representing 74% of all the mutations detected in Sardinia vs 37% in mainland Italy. These findings provide an updated fine-grained picture of 21OHD-CAH genetic epidemiology in Italy and suggest the need for a screening approach suitable to the detection of the largest number of clinically significant forms of CAH.

Published
2018

22. Rheumatoid Arthritis: Atherosclerosis Imaging and Cardiovascular Risk Assessment Using Machine and Deep Learning–Based Tissue Characterization

Author

Khanna, N.N. Jamthikar, A.D. Gupta, D. Piga, M. Saba, L. Carcassi, C. Giannopoulos, A.A. Nicolaides, A. Laird, J.R. Suri, H.S. Mavrogeni, S. Protogerou, A.D. Sfikakis, P. Kitas, G.D. Suri, J.S.

Abstract

Purpose of the Review: Rheumatoid arthritis (RA) is a chronic, autoimmune disease which may result in a higher risk of cardiovascular (CV) events and stroke. Tissue characterization and risk stratification of patients with rheumatoid arthritis are a challenging problem. Risk stratification of RA patients using traditional risk factor–based calculators either underestimates or overestimates the CV risk. Advancements in medical imaging have facilitated early and accurate CV risk stratification compared to conventional cardiovascular risk calculators. Recent Finding: In recent years, a link between carotid atherosclerosis and rheumatoid arthritis has been widely discussed by multiple studies. Imaging the carotid artery using 2-D ultrasound is a noninvasive, economic, and efficient imaging approach that provides an atherosclerotic plaque tissue–specific image. Such images can help to morphologically characterize the plaque type and accurately measure vital phenotypes such as media wall thickness and wall variability. Intelligence-based paradigms such as machine learning– and deep learning–based techniques not only automate the risk characterization process but also provide an accurate CV risk stratification for better management of RA patients. Summary: This review provides a brief understanding of the pathogenesis of RA and its association with carotid atherosclerosis imaged using the B-mode ultrasound technique. Lacunas in traditional risk scores and the role of machine learning–based tissue characterization algorithms are discussed and could facilitate cardiovascular risk assessment in RA patients. The key takeaway points from this review are the following: (i) inflammation is a common link between RA and atherosclerotic plaque buildup, (ii) carotid ultrasound is a better choice to characterize the atherosclerotic plaque tissues in RA patients, and (iii) intelligence-based paradigms are useful for accurate tissue characterization and risk stratification of RA patients. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.

Published
2019

23. Effect of carotid image-based phenotypes on cardiovascular risk calculator: AECRS1.0

Author

Khanna, N.N. Jamthikar, A.D. Gupta, D. Araki, T. Piga, M. Saba, L. Carcassi, C. Nicolaides, A. Laird, J.R. Suri, H.S. Gupta, A. Mavrogeni, S. Protogerou, A. Sfikakis, P. Kitas, G.D. Suri, J.S.

Abstract

Today, the 10-year cardiovascular risk largely relies on conventional cardiovascular risk factors (CCVRFs) and suffers from the effect of atherosclerotic wall changes. In this study, we present a novel risk calculator AtheroEdge Composite Risk Score (AECRS1.0), designed by fusing CCVRF with ultrasound image-based phenotypes. Ten-year risk was computed using the Framingham Risk Score (FRS), United Kingdom Prospective Diabetes Study 56 (UKPDS56), UKPDS60, Reynolds Risk Score (RRS), and pooled composite risk (PCR) score. AECRS1.0 was computed by measuring the 10-year five carotid phenotypes such as IMT (ave., max., min.), IMT variability, and total plaque area (TPA) by fusing eight CCVRFs and then compositing them. AECRS1.0 was then benchmarked against the five conventional cardiovascular risk calculators by computing the receiver operating characteristics (ROC) and area under curve (AUC) values with a 95% CI. Two hundred four IRB-approved Japanese patients’ left/right common carotid arteries (407 ultrasound scans) were collected with a mean age of 69 ± 11 years. The calculators gave the following AUC: FRS, 0.615; UKPDS56, 0.576; UKPDS60, 0.580; RRS, 0.590; PCRS, 0.613; and AECRS1.0, 0.990. When fusing CCVRF, TPA reported the highest AUC of 0.81. The patients were risk-stratified into low, moderate, and high risk using the standardized thresholds. The AECRS1.0 demonstrated the best performance on a Japanese diabetes cohort when compared with five conventional calculators. [Figure not available: see fulltext.]. © 2019, International Federation for Medical and Biological Engineering.

Published
2019

31. Predictive testing for Wilson's disease using tightly linked and flanking DNA markers

Author

Farrer, L.A., Bowcock, A.M., Hebert, J.M., Bonne-Tanir, B., Sternlieb, I., Giagheddu, M., St. George-Hyslop, P., Frydman, M., Lossner, J., Demelia, L., Carcassi, C., Lee, R., Beker, R., Bale, A.E., Donis-Keller, H., Scheinberg, I.H., and Cavalli-Sforza, L.L.

Subjects
Liver diseases -- Genetic aspects, Nervous system -- Abnormalities, Wilson's disease -- Genetic aspects, Chromosome mapping -- Research, Genetic disorders -- Cases, Health, Psychology and mental health
Abstract

Wilson's disease is a disorder of copper metabolism. The gene for Wilson's disease is especially common, and about 1 in 90 of all people carry this gene. Wilson's disease is recessive: the disease results when an individual inherits one of the disease genes from each of his or her parents. The gene for Wilson's disease is located on chromosome 13. Using the techniques of molecular biology, it is now possible to locate the gene within the chromosome with great precision. In the past, researchers could identify the location of a gene only when nearby genetic markers were available for correlation. Now it is possible to use DNA fragments to examine regions of chromosomes where classic markers are few and far between. Studying 52 families affected by Wilson's disease in North America, Europe, and the Middle East, it was possible to determine that the most likely location for the Wilson's disease gene was between two DNA markers on the long arm of chromosome 13, near q14. A larger number of families will have to be studied before the definitive assignment can be made. A clinically important result of this finding is that it may be possible to determine the likelihood of Wilson's disease in children who have not yet begun to develop symptoms. It should be emphasized that a true screening test has not been accomplished, but rather that the odds for a particular child in a family with a history of Wilson's disease may be calculated. For some genetic disorders, such a determination may be of only academic interest. But Wilson's disease may be treated with penicillamine, which binds excess copper that has accumulated and helps the body eliminate it. Therefore, the identification of children with the disorder prior to the development of symptoms may result in the early initiation of treatment with improved results. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

33. Role of HLA-G in autoimmune hepatitis

Author

Littera, R, Lai, S, Congeddu, E, Ragatzu, P, Cipri, S, Valentini, Md, Cappai, L, Porcella, R, Alba, F, Serra, M, Loi, V, Maddi, R, Melis, M, Cusano, R, Trucas, Marcello, Orru, S, Chessa, L, Onali, S, Figorilli, F, and Carcassi, C

Subjects
cholangitis, hepatltis, autoimmunity, HLA-G, Sardinia
Published
2018

39. Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population

Author

Mariani M, Malagoli A, Lombardo C, Iannone AM, Frison S, Dametto E, Cosentini E, Chiesa A, Carcassi C, Martinetti M, Cuccia MC, Testi M, Bontadini A, Mariotti L, Mascaretti L, Mele L, Miotti V, Nesci S, Ozzella G, Piancatelli D, Romeo G, Tagliaferri C, Vatta S, Andreani M, and Conte R

Subjects
Medicine
Abstract

Abstract Background Killer cell immunoglobulin-like receptors (KIRs) are a family of inhibitory and activatory receptors that are expressed by most natural killer (NK) cells. The KIR gene family is polymorphic: genomic diversity is achieved through differences in gene content and allelic polymorphism. The number of KIR loci has been reported to vary among individuals, resulting in different KIR haplotypes. In this study we report the genotypic structure of KIRs in 217 unrelated healthy Italian individuals from 22 immunogenetics laboratories, located in the northern, central and southern regions of Italy. Methods Two hundred and seventeen DNA samples were studied by a low resolution PCR-SSP kit designed to identify all KIR genes. Results All 17 KIR genes were observed in the population with different frequencies than other Caucasian and non-Caucasian populations; framework genes KIR3DL3, KIR3DP1, KIR2DL4 and KIR3DL2 were present in all individuals. Sixty-five different profiles were found in this Italian population study. Haplotype A remains the most prevalent and genotype 1, with a frequency of 28.5%, is the most commonly observed in the Italian population. Conclusion The Italian Caucasian population shows polymorphism of the KIR gene family like other Caucasian and non-Caucasian populations. Although 64 genotypes have been observed, genotype 1 remains the most frequent as already observed in other populations. Such knowledge of the KIR gene distribution in populations is very useful in the study of associations with diseases and in selection of donors for haploidentical bone marrow transplantation.

Published
2006
Full Text
View/download PDF

41. Impatto dei recettori KIR e dei suoi ligandi HLA sull’esito del trapianto di rene

Author

Littera, R., Argiolas, D., Gongeddu, E, Ragatzu, P., Loi, V., Serra, M., Maddi, R., Alba, F., Valentini, D., Porcella, R., Cappai, I., Lai, S., Orrù, S., Piredda, G., Pani, A., Frongia, M., Trucas, M., Piras, F., Cusano, R., and Carcassi, C.

Subjects
nk, patogenesi, immunity, kir, immunology, rigetto, rene, irc, graft, trapianto, cad, killer, engraftment, natural, rc
Published
2016

42. A genetic epidemiology study of congenital adrenal hyperplasia in Italy

Author

Gialluisi, A., primary, Menabò, S., additional, Baldazzi, L., additional, Casula, L., additional, Meloni, A., additional, Farci, M. C., additional, Mariotti, S., additional, Balestrino, L., additional, Ortolano, R., additional, Murru, S., additional, Carcassi, C., additional, Loche, S., additional, Balsamo, A., additional, and Romeo, G., additional

Published
2017
Full Text
View/download PDF

43. Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients

Author

Onali, S., primary, Littera, R., additional, Casale, M., additional, Capraro, F., additional, Balestrieri, C., additional, Figorilli, F., additional, Serra, G., additional, Congeddu, E., additional, Ragatzu, P., additional, Maddi, R., additional, Serra, M., additional, Loi, V., additional, Trucas, M., additional, Carcassi, C., additional, and Chessa, L., additional

Published
2017
Full Text
View/download PDF

44. HLA-G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis

Author

Onali, S., primary, Figorilli, F., additional, Sanna, E., additional, Balestrieri, C., additional, Serra, G., additional, Conti, M., additional, Alba, F., additional, Trucas, M., additional, Fanni, D., additional, Senes, G., additional, Mereu, A., additional, Faa, G., additional, Carcassi, C., additional, Littera, R., additional, and Chessa, L., additional

Published
2017
Full Text
View/download PDF

45. Impact of natural killer cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients

Author

Onali, S., primary, Littera, R., additional, Casale, M., additional, Capraro, F., additional, Figorilli, F., additional, Balestrieri, C., additional, Serra, G., additional, Congeddu, E., additional, Ragatzu, P., additional, Maddi, R., additional, Serra, M., additional, Loi, V., additional, Trucas, M., additional, Carcassi, C., additional, and Chessa, L., additional

Published
2017
Full Text
View/download PDF

47. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the 'Euro-Lupus Project'

Author

Cervera, R, ABARCA-COSTALAGO, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, Ao, Bacarelli, Mr, Bellisai, F, Bernardino, I, BIERNAT-KALUZA, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, Mt, Carcassi, C, Cattaneo, R, Cauli, A, CHWALINSKA-SADOWSKA, H, Contu, L, Cosyns, Jp, Danieli, Mg, Dcruz, D, Depresseux, G, Direskeneli, H, Domenech, I, Espinosa, G, FERNANDEZ-NEBRO, A, Ferrara, Gb, Font, J, Frutos, Ma, Galeazzi, M., GARCIA-CARRASCO, M, GARCIA IGLESIAS MF, GARCIA-TOBARUELA, A, George, J, Gil, A, GONZALEZ-SANTOS, P, Grana, M, Gul, A, Haga, Hj, DE HARO-LIGER, M, Houssiau, F, Hughes, Gr, Ingelmo, M, JEDRYKA-GORAL, A, Khamashta, Ma, Lavilla, P, Levi, Y, LOPEZ-DULPA, M, LOPEZ-SOTO, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perello, I, Petera, P, Petrovic, R, Piette, Jc, Pintado, V, DE PITA, O, Popovic, R, Pucci, G, Puddu, P, DE RAMON, E, RAMOS-CASALS, M, RODRIGUEZ-ANDREU, J, RUIZ-IRASTORZA, G, SANCHEZ-LORA, J, Sanna, G, Scorza, R, Sebastiani, Gd, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, Ra, Smolen, J, Tincani, A, Tokgoz, G, URBANO-MARQUEZ, A, Vasconcelos, C, Vazquez, Jj, Veronesi, J, Vianna, J, Vivancos, J, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service de rhumatologie, UCL - MD/MNOP - Département de morphologie normale et pathologique, UCL - (SLuc) Service d'anatomie pathologique, Cervera, R, Abarca Costalago, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, A, Bacarelli, M, Bellisai, F, Bernardino, I, Biernat Kaluza, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, M, Carcassi, C, Cattaneo, R, Cauli, A, Chwalinska Sadowska, H, Contu, L, Cosyns, J, Danieli, M, D́cruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, Fernández Nebro, A, Ferrara, G, Font, J, Frutos, M, Galeazzi, M, García Carrasco, M, García Iglesias, M, García Tobaruela, A, George, J, Gil, A, González Santos, P, Grana, M, Gül, A, Haga, H, de Haro Liger, M, Houssiau, F, Hughes, G, Ingelmo, M, Jedryka Góral, A, Khamashta, M, Lavilla, P, Levi, Y, López Dupla, M, López Soto, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, J, Pintado, V, de Pita, O, Popovic, R, Pucci, G, Puddu, P, de Ramón, E, Ramos Casals, M, Rodríguez Andreu, J, Ruiz Irastorza, G, Sánchez Lora, J, Sanna, G, Scorza, R, Sebastiani, G, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, R, Smolen, J, Tincani, A, Tokgöz, G, Urbano Márquez, A, Vasconcelos, C, Vázquez, J, Veronesi, M, Vianna, J, and Vivancos, J

Subjects
Male, medicine.medical_specialty, Prognosi, Epidemiology, Immunology, Systemic lupus erythematosu, Disease, Prognostic factors, Autoimmune Disease, Follow-Up Studie, Autoimmune Diseases, Cohort Studies, Systemic lupus erythematosus, immune system diseases, medicine, Immunology and Allergy, Humans, Lupus Erythematosus, Systemic, Prospective Studies, Age of Onset, Mortality, Prospective cohort study, skin and connective tissue diseases, Survival rate, Prognostic factor, business.industry, medicine.disease, Prognosis, Europe, Survival Rate, Prospective Studie, Family medicine, Antibodies, Antinuclear, Cohort, Female, Cohort Studie, Age of onset, Morbidity, business, Human, Cohort study, Follow-Up Studies
Abstract

The "Euro-Lupus Cohort" is composed by 1000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium-the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors. © 2005 Elsevier B.V. All rights reserved.

Published
2006

49. Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients

Author

Caocci, G, Martino, B, Greco, M, Abruzzese, E, Trawinska, M, Lai, S, Ragatzu, P, Galimberti, S, Baratè, C, Mulas, O, Labate, C, Littera, R, Carcassi, C, GAMBACORTI PASSERINI, C, La Nasa, G, La Nasa, G., GAMBACORTI PASSERINI, CARLO, Caocci, G, Martino, B, Greco, M, Abruzzese, E, Trawinska, M, Lai, S, Ragatzu, P, Galimberti, S, Baratè, C, Mulas, O, Labate, C, Littera, R, Carcassi, C, GAMBACORTI PASSERINI, C, La Nasa, G, La Nasa, G., and GAMBACORTI PASSERINI, CARLO

Abstract

Several factors are predictive of treatment-free remission (TFR) in chronic myeloid leukemia (CML), but few data exist on the role of natural killer (NK) cells and their killer-cell immunoglobulin-like receptors (KIRs). KIR and human leukocyte antigen (HLA) genotypes were investigated in 36 CML patients who discontinued tyrosine kinase inhibitor (TKI) treatment after achieving deep molecular response (MR4.5). Cumulative TFR was significantly higher in patients homozygous for KIR A haplotype (85.7% vs. 45.5%; p = 0.029). Younger age, Bx haplotype, and the combination KIR3DS1/KIR3DL1 present/HLA-Bw4 present were significantly associated with relapse. KIR genotypes could prove useful in identifying patients that are likely to maintain MR4.5 after discontinuing TKI treatment.

Published
2015

50. Lessons from the 'Euro-Lupus Cohort'

Author

Cervera, R., Abarca Costalago, M., Abramovicz, D., Allegri, F., PASQUALE ANNUNZIATA, Aydintug, Ao, Bacarelli, Mr, Bellisai, F., Bernardino, I., Biernat Kaluza, E., Blockmans, D., Boki, K., LUISA BRACCI, Campanella, V., Camps, Mt, Carcassi, C., Cattaneo, R., Cauli, A., Chwalinska Sadowska, H., Contu, L., Cosyns, Jp, Danieli, Mg, D Cruz, D., Depresseux, G., Direskeneli, H., Domènech, I., Espinosa, G., Fernández Nebro, A., Ferrara, Gb, Font, J., Frutos, Ma, MAURO GALEAZZI, García Carrasco, M., GARCÍA IGLESIAS MF, García Tobaruela, A., George, J., Gil, A., González Santos, P., Grana, M., Gül, A., Haga, Hj, Haro Liger, M., Houssiau, F., Hughes, Gr, Ingelmo, M., Jedryka Góral, A., Khamashta, Ma, Lavilla, P., Levi, Y., López Dupla, M., López Soto, A., Maldykowa, H., Marcolongo, R., Mathieu, A., GABRIELLA MOROZZI, Nicolopoulou, N., Papasteriades, C., Passiu, G., Perelló, I., Petera, P., Petrovic, R., Piette, Jc, Pintado, V., Pita, O., Popovic, R., Pucci, G., Puddu, P., Ramón, E., Ramos Casals, M., Rodríguez Andreu, J., Ruiz Irastroza, G., Sánchez Lora, J., Sanna, G., Scorza, R., Sebastini, Gd, Sherer, Y., Shoenfeld, Y., Simpatico, A., Sinico, Ra, Smolen, J., Tincani, A., Tokgöz, G., Urbano Márquez, A., Vasconcelos, C., Vázquez, Jj, Veronesi, M., Vianni, J., Vivancos, J., EUROPEAN WORKING PARTY ON SYSTEMIC LUPUS ERYTHEMATOSUS, Cervera, R, Abarca Costalago, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, A, Bacarelli, M, Bellisai, F, Bernardino, I, Biernat Kaluza, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, M, Carcassi, C, Cattaneo, R, Cauli, A, Chwalinska Sadowska, H, Contu, L, Cosyns, J, Danieli, M, D'Cruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, Fernández Nebro, A, Ferrara, G, Font, J, Frutos, M, Galeazzi, M, García Carrasco, M, García Iglesias, M, García Tobaruela, A, George, J, Gil, A, González Santos, P, Grana, M, Gül, A, Haga, H, de Haro Liger, M, Houssiau, F, Hughes, G, Ingelmo, M, Jedryka Góral, A, Khamashta, M, Lavilla, P, Levi, Y, López Dupla, M, López Soto, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, J, Pintado, V, de Pita, O, Popovic, R, Pucci, G, Puddu, P, de Ramón, E, Ramos Casals, M, Rodríguez Andreu, J, Ruiz Irastroza, G, Sánchez Lora, J, Sanna, G, Scorza, R, Sebastini, G, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, R, Smolen, J, Tincani, A, Tokgöz, G, Urbano Márquez, A, Vasconcelos, C, Vázquez, J, Veronesi, M, Vianni, J, and Vivancos, J

Subjects
Adult, Male, Adolescent, Prognosi, Middle Aged, Prognosis, Cohort Studies, Europe, Survival Rate, Prospective Studie, Antibodies, Antinuclear, Humans, Lupus Erythematosus, Systemic, Female, Prospective Studies, Cohort Studie, Age of Onset, Human
Abstract

The "Euro-Lupus Cohort" is composed by 1,000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium - the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results